Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Image Credit: Albumedix Ltd.

This announcement comes on the back of the recent approval of Valneva´s inactivated COVID-19 vaccine (VLA2001) by MHRA, for which Valneva signed an agreement in November 2021 with the European Commission to supply up to 60 million doses over 2 years, as well as announcing an advance purchase agreement with the Kingdom of Bahrain in December 2021 for the supply of one million doses.

Albumedix Recombumin® rHA is an essential component in VLA2001, used in the manufacturing process and final formulation of the vaccine. The companies began their collaboration with the inclusion of Recombumin® in Valneva’s single-shot vaccine candidate against the mosquito-borne viral infection chikungunya, VLA1553, which successfully completed its pivotal Phase 3 trial in March 2022. Both companies are committed to producing safe, effective and scalable vaccines.

We are excited to expand our relationship with a valued partner like Valneva, thereby continuing to leverage our long track record of supporting vaccine companies in their development of safe and scalable vaccines. In the last 2 years, it has been incredible to witness and partake in the monumental achievements realized by the life science industry through purpose-led collaborations like the one we share with Valneva.” 

Jonas Skjødt Møller, Chief Executive Officer, Albumedix.

We wholeheartedly welcome the contribution that Albumedix is making to the manufacture of our newly approved inactivated, whole virus COVID-19 vaccine – the first of its kind developed in Europe. Our collaboration is enabling the development of vaccines to address significant unmet medical need, including this differentiated COVID-19 vaccine option for populations and physicians who need it.”

Vincent Dequenne, Chief Operating Officer, Valneva.

Albumin is an established enabler of advanced therapies and biopharmaceuticals and the properties of Recombumin® are shown to be beneficial across a broad range of vaccine modalities. Consequently, Albumedix´ rHA´s are already included in a range of vaccine candidates in clinical development and marketed vaccines, resulting in more than 210 million safe injections with Recombumin®.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the pandemic and for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. VLA2001’s manufacturing process, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 to 8 degrees Celsius). 

About Recombumin®

The Recombumin® product portfolio are the highest quality, animal and human origin-free recombinant human albumins commercially available. Albumin is a multi-functional excipient and its stabilization properties have been validated through its long-established use in multiple marketed products. Albumedix´ highly pure, safe and consistent albumins enable you to formulate with confidence.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Albumedix Ltd.. (2024, March 12). Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine. News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/news/20230629/Albumedix-and-Valneva-expand-collaboration-to-include-newly-approved-inactivated-COVID-19-vaccine.aspx.

  • MLA

    Albumedix Ltd.. "Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine". News-Medical. 18 April 2024. <https://www.news-medical.net/news/20230629/Albumedix-and-Valneva-expand-collaboration-to-include-newly-approved-inactivated-COVID-19-vaccine.aspx>.

  • Chicago

    Albumedix Ltd.. "Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine". News-Medical. https://www.news-medical.net/news/20230629/Albumedix-and-Valneva-expand-collaboration-to-include-newly-approved-inactivated-COVID-19-vaccine.aspx. (accessed April 18, 2024).

  • Harvard

    Albumedix Ltd.. 2024. Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine. News-Medical, viewed 18 April 2024, https://www.news-medical.net/news/20230629/Albumedix-and-Valneva-expand-collaboration-to-include-newly-approved-inactivated-COVID-19-vaccine.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences